BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

CAR-T therapy targeting TM4SF1 in aggressive bladder cancer (HV) histologic variant , offering hope for treatment-resistant ...

Scientists found a way to identify and possibly treat a mysterious type of bladder cancer that affects up to 1 in 4 cases.

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

enGene Holdings shares were up 7% to $3.25 after the company said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid.

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | ...

With topical estrogen, the vaginal flora returns back to the premenopausal stage with less E. coli -- a common cause of ...

“Pelvic floor therapy is like physical therapy to strengthen all the muscles and tissues in your pelvis that can become weak ...

Bladder cancer can be a silent killer, often presenting few symptoms in its early stages. Learn about the disease, its early symptoms, and more.